Drug profile · INN
taletrectinib adipate
IBTROZI
taletrectinib adipate (IBTROZI) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Drug details — taletrectinib adipate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
taletrectinib adipate (IBTROZI) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Frequently asked questions
What is taletrectinib adipate?
taletrectinib adipate (IBTROZI) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for taletrectinib adipate?
IBTROZI is a marketed brand name for taletrectinib adipate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of taletrectinib adipate?
taletrectinib adipate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.